Nevertheless, in light of recent evidence indicating that SRC-2 has oncogenic activity in prostate cancer [27], a direct demonstration of the tumor suppressor activity of SRC-2 in liver cancer, and a better understanding of the underlying mechanisms, would provide important insight into the role of SRC-2 in HCC. Here, NCOA2 is linked to prostate cancer.